Related references
Note: Only part of the references are listed.Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long-term Use study
Kazuyuki Tobe et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
Binayak Sinha et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
Ichiro Nakamura et al.
ADVANCES IN THERAPY (2019)
SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis
Man Guo et al.
DIABETES OBESITY & METABOLISM (2018)
Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
Kohei Kaku et al.
CIRCULATION JOURNAL (2017)
Share Paper
